scholarly journals Serum interleukin-17 and estradiol levels in postmenopausal women in relation to osteoporosis

2021 ◽  
Vol 48 (1) ◽  
Author(s):  
Reem El-Mallah ◽  
Azza A. Saab ◽  
Nagwa Nassar
Keyword(s):  
Postmenopausal Women ◽  
Predictive Value ◽  
Animal Studies ◽  
Significant Negative Correlation ◽  
Estrogen Deficiency ◽  
Interleukin 17 ◽  
Mineral Density ◽  
Estrogen Level ◽  
Significant Difference ◽  
Post Menopausal

Abstract Background In post-menopausal women, estrogen deficiency leads to instability between bone formation and resorption which is regulated by osteoclastogenic cytokines leading to resorption. Interleukin-17 (IL-17) a proinflammatory cytokine has been found as an important regulator of osteoclast-genesis induced by estrogen deficiency in favor of bone loss in animal studies. The study aimed to evaluate levels of IL-17 and estrogen (E2) in relation to bone mineral density (BMD) and risk of fracture in postmenopausal women with and without osteoporosis. Results IL-17 levels were significantly higher and E2 levels were significantly lower in the osteoporotic group compared to the non-osteoporotic group (P value ≤ 0.01). There was a highly significant difference in DEXA score and FRAX index between two groups: with higher values of FRAX and lower values of DEXA score among osteoporotic group (P value ≤ 0.01). IL-17 was inversely correlated to estrogen level and highly significant negative correlation with DEXA as well as a highly significant positive one with FRAX index. IL-17 serum level was able to diagnose osteoporosis at a cutoff level of > 80 pg/mL with 100% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 100% negative predictive value (NPV). Conclusions Serum IL-17 was significantly elevated in osteoporotic postmenopausal women when compared to healthy postmenopausal ones and was inversely correlated with estrogen level and DEXA.

scholarly journals Prevalence of osteoporosis and osteoporotic fractures in postmenopausal women with type 2 diabetes mellitus

2021 ◽  
Vol 3 (3) ◽  
Author(s):  
Lamia Oulkadi ◽  
Bouchra Amine ◽  
Imane El binoune ◽  
Samira Rostom ◽  
Rachid Bahiri
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Postmenopausal Women ◽  
Mineral Density ◽  
Control Subjects ◽  
Increased Risk ◽  
Significant Difference ◽  
Prevalence Of Osteoporosis

Type 2 diabetes mellitus (T2DM) and osteoporosis are chronic diseases with increasing prevalence. The aim of this study was to determine the prevalence of osteoporosis and osteoporotic fracture in women with T2DM and to identify predictive factors of fracture occurrence. The prevalence of osteoporosis and fractures in postmenopausal women with T2DM was 23.1% and 16.9%, respectively. 46.2% of T2DM patients had normal bone mineral density (BMD) (P<0.01) and 58.5% of control subjects had osteopenia (P<0.01). Incidence of fracture in T2DM patients with osteopenia was significantly increased versus control subjects when stratified according the BMD (P=0.009). By stratifying T2DM patients according to fractures, factors that were significantly associated with occurrence included T2DM duration (P=0.038), use of insulin (P=0.017), and lower BMD (P=0.048). Our study suggests that there was a higher prevalence of fracture in T2DM patients compared to control subjects and a significant difference in BMD was found between the groups. We also showed that insulin use, low BMD, and long duration of T2DM are factors associated with an increased risk of bone fracture.

scholarly journals Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis

2017 ◽  
pp. E146-E157 ◽  
Author(s):  
Chun-Lin Liu ◽  
Han-Chung Lee ◽  
Chun-Chung Chen ◽  
Der-Yang Cho
Keyword(s):  
Lumbar Spine ◽  
Femoral Neck ◽  
Treatment Effectiveness ◽  
Meta Analysis ◽  
Mineral Density ◽  
Total Hip ◽  
Nonvertebral Fractures ◽  
Post Menopausal Osteoporosis ◽  
Significant Difference ◽  
Post Menopausal

Purpose: This meta-analysis aimed to compare the efficacy and safety of teriparatide vs. bisphosphonates in the management of osteoporosis. Methods: A total of 1,967 patients from eight randomized controlled trials were analyzed; outcomes included bone mineral density (BMD) of the femoral neck, total hip and lumbar spine, vertebral and nonvertebral fractures and any adverse event. A subgroup analysis of treatment effectiveness was performed according to the etiology of osteoporosis; i.e., glucocorticoid-induced osteoporosis (GIO) vs. post-menopausal osteoporosis (PO). Results: Teriparatide increased the BMD of the lumbar spine, femoral neck and total hip to a greater extent than bisphosphonates. Patients treated with teriparatide also had a lower risk of vertebral fractures compared with bisphosphonates; however, no difference in risk of nonvertebral fractures (or adverse events) was found. GIO subgroups showed larger increases in BMD of the lumbar spine, total hip and femoral neck in patients treated with teriparatide compared with bisphosphonates. The PO subgroup showed larger increases in BMD of the lumbar spine in patients treated with teriparatide compared with bisphosphonates. Patients in the GIO subgroup (but not the PO subgroup) were less likely to suffer a vertebral fracture on teriparatide as compared with bisphosphonates. In contrast, no significant difference in the percentage of nonvertebral fractures was noted between the two types of treatment for either subgroup. Conclusion: Teriparatide significantly increased the BMD of lumbar spine, total hip and femoral neck, particularly in GIO-induced osteoporosis. Teriparatide did not lower the risk of nonvertebral fractures when compared with bisphosphonates.

scholarly journals Influence of Number of Parity on Bone Mineral Density among Postmenopausal Women

2016 ◽  
Vol 33 (2) ◽  
pp. 75-78
Author(s):  
Irin Parveen Alam ◽  
Mohd Azharul Haque ◽  
Saleha Begum Chowdhury
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Significant Negative Correlation ◽  
Common Disease ◽  
Mineral Density ◽  
T Score ◽  
Femur Neck ◽  
Considerable Morbidity ◽  
Age Range

Introduction- Osteoporosis is a common disease of postmenopausal women and is responsible for considerable morbidity and mortality. The most important single determining factor is low bone mass. Generally accepted risk factors of osteoporosis in women are low body weight, age, low physical activity and cigarette smoking. The effect of parity is controversial.Objective-The main objective of the study was to assess the influence of parity on bone mineral density among the postmenopausal women.Methods-In this study total 75 postmenopausal women aged 51-70 years of with parity 1-13 were studied. Parity was described as the number of births reported by the women. In Journal of Bangladesh College of Physicians and Surgeons Vol. 33, No. 2, April 2015 this study T score of BMD of different bony sites lumber vertebrae and femur were analyzed. BMD were measured in the Institute of Nuclear Medicine at BSMMU. Correlations between BMD values with parity were detected.Results- The mean age of the patients was 60 years with a standard deviation of ±9.32 years. All patients were within 51 to 70 years age range. A significant negative correlation was found in present study between parity and the T score measurement results obtained from L2, L3, L4, L2-4, Femur neck, Trochantor and Ward’s triangle. This shows mean Tscore of BMD were more negative as number of parity increases.J Bangladesh Coll Phys Surg 2015; 33(2): 75-78Introduction- Osteoporosis is a common disease of postmenopausal women and is responsible for considerable morbidity and mortality. The most important single determining factor is low bone mass. Generally accepted risk factors of osteoporosis in women are low body weight, age, low physical activity and cigarette smoking. The effect of parity is controversial. Objective-The main objective of the study was to assess the influence of parity on bone mineral density among the postmenopausal women. Methods-In this study total 75 postmenopausal women aged 51-70 years of with parity 1-13 were studied. Parity was described as the number of births reported by the women. In Journal of Bangladesh College of Physicians and Surgeons Vol. 33, No. 2, April 2015 this study T score of BMD of different bony sites lumber vertebrae and femur were analyzed. BMD were measured in the Institute of Nuclear Medicine at BSMMU. Correlations between BMD values with parity were detected. Results- The mean age of the patients was 60 years with a standard deviation of ±9.32 years. All patients were within 51 to 70 years age range. A significant negative correlation was found in present study between parity and the T score measurement results obtained from L2, L3, L4, L2-4, Femur neck, Trochantor and Ward’s triangle. This shows mean Tscore of BMD were more negative as number of parity increases.J Bangladesh Coll Phys Surg 2015; 33(2): 75-78

Potential role of FRAX analysis in postmenopausal women with osteopenia

Open Medicine ◽  
2011 ◽  
Vol 6 (2) ◽  
pp. 185-189
Author(s):  
Aleksandar Dimić ◽  
Stojanovic Sonja ◽  
Nedovic Jovan ◽  
Stankovic Aleksandra ◽  
Stamenkovic Bojana ◽  
...  
Keyword(s):  
Hip Fracture ◽  
High Risk ◽  
Postmenopausal Women ◽  
Hip Fractures ◽  
Potential Role ◽  
Osteoporotic Fractures ◽  
Significant Negative Correlation ◽  
Mineral Density ◽  
Fracture Development

AbstractEarly diagnosis of osteoporosis and estimation of subjects that are at high risk for fracture, is neccesary for osteoporosis treatment. Dual-energy X-ray absorptometry (DXA) is a modern method for bone mineral density (BMD) evaluation. However, along BMD, clinical risk factors may significantly influence fracture development. Therefore, FRAX algorithm was designed for the assessment of a ten-year risk for serious osteoporotic fractures (SOF), as well as hip fractures. In the current study, we tried to evaluate the possible lumbal spine and hip BMD influence on ten year risk for SOF and hip fractures and potential role of FRAX in predicting the therapy in postmenopausal women with osteopenia. We performed the study on 385 postmenopausal women. According to the DXA measurements, at the lumbal (L) spine (L1–L4) and hip (femor neck), patients were then classified as normal, osteopenic, or osteoporotic. BMD evaluation included the L spine and the hip (subgroup 1), and only on the L spine (subgroup 2). By filling up the FRAX questionnaire, a ten-year risk for SOF fracture and hip fracture was calculated. BMD evaluation, in complete patient’s group and in subgroup 1, resulted in the highest number of osteoporosis (61.04%, 48.08%, retrospectively), while ospeopenia was a main finding in subgroup 2. In the subgroup 1, a high risk for SOF and hip fracture was detected in 16.45% and with high risk for hip fracture in 11.38% subjects. In subgroup 2, only high risk for hip fracture was observed in 3.16% subjects, indicating the active medicament treatment. Simultaneously, correlation of BMD results with FRAX values for SOF and hip fracture, showed significant negative correlation (p<0.001). Obtained results showed significant role of femur neck BMD evaluation in predicting the future factors, which may, together with FRAX analysis, improve the therapy approach in postmenopausal women with ospeopenia.

scholarly journals Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 53 (11) ◽  
pp. 730-737
Author(s):  
Hao-Yang Ma ◽  
Shuang Chen ◽  
Ling-Ling Lu ◽  
Wei Gong ◽  
Ai-Hua Zhang
Keyword(s):  
Lumbar Spine ◽  
Renal Disease ◽  
Postmenopausal Women ◽  
End Stage Renal Disease ◽  
Control Group ◽  
Mineral Density ◽  
Treatment Of Osteoporosis ◽  
Significant Difference ◽  
Stage Renal Disease ◽  
End Stage

AbstractAs a selective estrogen receptor modulator (SERM), raloxifene is used in healthy postmenopausal women to prevent bone loss and reduce fractures. However, the benefit of raloxifene is uncertain in the treatment of osteoporosis among patients with end-stage renal disease (ESRD) or those who require maintenance dialysis. We assessed the safety and efficacy of raloxifene in this particular population. Studies were selected from PubMed, Springer, CNKI (Chinese National Knowledge Infrastructure) and Wanfang Database. Randomized controlled trials (RCTs) and prospective studies with control/placebo groups were included. Five studies were included with a total of 244 participants (121 patients in the raloxifene group and 123 patients in the placebo/control group). The median duration of treatment was 12 months. The incidence rate of side effects of raloxifene was 0/121 (0%). There was a significant improvement of lumbar spine bone mineral density (BMD) levels in the raloxifene group compared with the placebo group (MD: 33.88, 95% CI: 10.93, 56.84, p=0.004). There was no significant difference concerning the improvement of femoral neck BMD (MD: 8.42, 95% CI: –10.21, 27.04, p=0.38), intact parathyroid hormone (iPTH) (MD: –12.62, 95% CI: –35.36, 10.13, p=0.28), calcium (MD: -0.08, 95% CI: –0.61, 0.44, p=0.76), phosphorus (MD: 0.18, 95% CI: –0.12, 0.48, p=0.23) or bone alkaline phosphatase (BAP) (MD: –4.33, 95% CI: –14.44, 5.79, p=0.40). Raloxifene seems to be effective in improving the lumbar spine BMD in postmenopausal women with ESRD. More large RCTs are necessary to evaluate the long-term safety of raloxifene in uremic patients.

scholarly journals A randomized clinical trial on improving osteopenia in postmenopausal women after two years of preventive treatment with alendronate; a dose of 35 mg per week is more effective or a dose of 70 mg?

2020 ◽  
Vol 5 (1) ◽  
pp. e16-e16
Author(s):  
Mansoor Karimifar ◽  
Negar Botlani ◽  
Amirhossein Salari
Keyword(s):  
Clinical Trial ◽  
Postmenopausal Women ◽  
Randomized Clinical Trial ◽  
Assessment Tool ◽  
Preventive Treatment ◽  
Weekly Dose ◽  
Mineral Density ◽  
Main Complaint ◽  
Gastrointestinal Problems ◽  
Significant Difference

Introduction: Osteoporosis is the most common metabolic bone disease worldwide. In this disease, the bone mass decreases and as it progresses, the risk of fracture increases. Osteopenia occurs in the early stages of bone loss. Studies on the effective dose for treatment of osteopenia have been controversial. Objectives: In this randomized clinical trial, low doses versus high doses of alendronate were assessed during the osteopenic stage in postmenopausal women. Patients and Methods: The present study is a randomized clinical trial (RCT) that was performed on 152 postmenopausal women who were visited in Al-Zahra rheumatology clinic between 2016 and 2017. Patients were randomly divided into two groups. The first group with 35 and the second group with 70 mg of weekly alendronate were treated and followed for two years. Densitometry was performed on patients before and 2 years after the intervention, and the findings were compared. Results: The two groups were not significantly different in terms of age, gender, height, weight, body mass index (BMI) and menopause (P>0.05). The bone mineral density (BMD) findings of both groups, including Fracture Risk Assessment Tool (FRAX) hip and vertebra/wrist, T-score hip and vertebrae, as well as Z-score hip and vertebrae, improved significantly after two years (P<0.001), However, a comparison of the two therapeutic doses did not show a significant difference in terms of BMD improvements (P>0.05). Conclusion: The findings of this study reported favorable results for the preventive treatment of alendronate in osteopenic women. In addition, due to gastrointestinal problems that are the main complaint of alendronate use, according to the results, a weekly dose of 35 mg can be recommended

scholarly journals Evaluation of bone mineral density and its correlation with homocysteine and other biochemical bone markers in postmenopausal women

2018 ◽  
Vol 4 (5) ◽  
pp. 709
Author(s):  
Gopinath P. ◽  
Abdul Ravoof
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Markers ◽  
Serum Alkaline Phosphatase ◽  
Plasma Concentrations ◽  
Mineral Density ◽  
Menopausal Women ◽  
Biochemical Bone Markers ◽  
Post Menopausal

<p class="abstract"><strong>Background:</strong> Osteoporosis is more common in post-menopausal women. Early detection of bone loss by bone mineral density helps to confirm the diagnosis of osteoporosis and assesses the future risk of osteoporotic fractures. Recent studies have revealed the association between increased plasma concentrations of homocysteine (Hcy), and reduced bone mineral density. Nevertheless, inconsistencies persist in the literature. Thus, the need for this study arose to investigate the possible relationship between serum Hcy status and bone mineral density on a group of post-menopausal women.<strong> </strong>The objective of the study was to assess bone mineral density (BMD) in postmenopausal women and to correlate the same with biochemical bone markers like homocysteine, serum alkaline phosphatase (ALP), calcium and phosphorous levels.</p><p class="abstract"><strong>Methods:</strong> One hundred (100) postmenopausal women were recruited to enter this cross-sectional study. Out of which 86 postmenopausal females, were grouped into osteopenic and osteoporotic based on low t –scores. Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DEXA) and serum Hcy, serum ALP, calcium and phosphorus levels were estimated. The relationship of Hcy with BMDand other biochemical markers was estimated using Pearson’s correlation.<strong></strong></p><p class="abstract"><strong>Results:</strong> Serum Hcy levels were significantly higher in osteoporotic women when compared to other BMD groups, and were inversely correlated with BMD. No statistical difference was seen with other biochemical bone markers like calcium, Phosphorus and ALP.</p><p class="abstract"><strong>Conclusions:</strong> This study shows that Hcy status is associated with BMD in osteoporotic postmenopausal women. BMD evaluation in postmenopausal women with high Hcy levels may have prognostic and therapeutic potentials, which needs to be explored through further Prospective studies.</p>

scholarly journals Relationship Of FEF25-75, Pefr And SVC With Estrogen And Progesterone Level In Postmenopausal Women

1970 ◽  
Vol 6 (2) ◽  
pp. 116-121 ◽  
Author(s):  
Zinat Ara Polly ◽  
Shelina Begum ◽  
Sultana Ferdousi ◽  
Noorzahan Begum ◽  
Taskina Ali ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Negative Correlation ◽  
Luteal Phase ◽  
Premenopausal Women ◽  
Follicular Phase ◽  
Progesterone Level ◽  
Serum Progesterone ◽  
Estrogen Level ◽  
Menopausal Women ◽  
Post Menopausal

Background: Deterioration of lung function is common in women after menopause, which may be related to very low estrogen and progesterone level. Objective: To observe FEF25-75, PEFR and SVC (slow vital capacity) values in apparently healthy postmenopausal women to find out their relationships with serum estrogen and progesterone. Methods: This study was carried out in the Department of Physiology in BSMMU, Dhaka in the year 2007. 30 healthy postmenopausal women aged 45 to 60 years and 30 healthy premenopausal women aged 20 to 30 years during their different phases of menstrual cycle were studied. Postmenopausal women were residents of Dhaka city and premenopausal subjects were medical students. FEF25-75, PEFR and SVC of all subjects were measured by a digital micro spirometer. Their estrogen and progesterone levels were estimated by Micro particle Enzyme Immunoassay (MEIA) method. Data were analyzed by Pearson’s correlation coefficient test, one way ANOVA and unpaired‘t’ test Results: The mean percentage of predicted values of FEF25-75 and PEFR were lower in postmenopausal women compared to those of follicular and luteal phases of premenopausal women but it was not significant. Measured values of SVC was Significantly (p<.001) lower in postmenopausal women compared to those of follicular and luteal phases of premenopausal women. Again Mean serum estrogen and progesterone levels were significantly (p<.001) lower in post menopausal women compared to those of follicular and luteal phases of premenopausal women. In post menopausal women, FEF25-75 was positively, PEFR and SVC were negatively correlated with progesterone level. PEFR and SVC showed positive correlattion and FEF25-75 showed negative correlation with serum estrogen level. All these correlations were statistically non significant. In premenopausal women FEF25-75 and PEFR showed positive correlation and SVC showed negative correlation with serum progesterone level. The relationships were statistically significant in luteal phase but nonsignificant in follicular phase. FEF25-75 ,PEFR and SVC were positively correlated with serum estrogen level in luteal phase but FEF25-75 and PEFR negatively correlated and SVC positively correlated with estrogen level in follicular phase. Conclusion: The outcome of this study shows FEF25-75 , PEFR and SVC may be reduced in postmenopausal women which in turn may be associated with their low progesterone and estrogen levels. DOI: http://dx.doi.org/10.3329/jbsp.v6i2.9761 JBSP 2011 6(2): 116-121

scholarly journals The effect of different exercise programs on bone mineral density and physical function in women with osteoporosis: A randomized controlled trial

2017 ◽  
Vol 1 (1) ◽  
pp. 47
Author(s):  
Lumnije Hoxha Kamberi
Keyword(s):  
Bone Mineral Density ◽  
Muscle Strength ◽  
Physical Function ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Controlled Trial ◽  
Intervention Group ◽  
Control Group ◽  
Mineral Density ◽  
Significant Difference

Aim: Osteoporosis is a multifactorial progressive skeletal disorder characterized by reduced bone mass. Exercise is widely recommended to reduce osteoporosis, falls and related fragility fractures. The purpose of this study was to investigate the effects of land exercise (LE) and aquatic exercise (AE) on physical function and bone mineral density (BMD). Methods: Fifty-eight postmenopausal women, aged 50-70 years,  diagnosed with osteoporosis according to BMD measures, enrolled in this study. The subjects were randomly assigned to either the intervention group (LE group) or the control group (AE group). Physical function and BMD were assessed in all subjects in both groups before and after 10 months of intervention. The muscle strength,   flexibility, balance, gait time and pain were measured to assess physical function. Bone mineral density at the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA). Results: There were no significant differences between the two groups in the baseline anthropometric data. The two groups were similar with respect to age, weight, height, and body mass index (p>0.05). After the exercise program, muscle strength, flexibility, gait time, pain, and bone density (p<0.001)  significantly improved with LE compared to AE. There was no significant difference between the two groups in balance at the 10-month follow-up. Conclusion: Significant improvements in physical function and BMD suggest that LE is a possible alternative for     postmenopausal women with OP. Clinical rehabilitation impact: In the current  available literature there is insufficient data regarding combined regimens,       additionally, conclusions from our research can inspire further studies in order to promote land and water based exercise.

Sign in / Sign up

Export Citation Format

Share Document